MindMed Archives | the deep dive

MindMed Acquires HealthMode For $41.6 Million

February 18, 2021 8:21 AMFebruary 18, 2021 8:21 AM Jay Lutz 0 Comments Mind Medicine, MindMed

MindMed (NEO: MMED) this morning announced that it will be acquiring that of HealthMode in a largely stock-based transaction. HealthMode

Briefing Psychedelics

MindMed Begins Study On LSD Neutralizer Technology

February 17, 2021 8:18 AMFebruary 17, 2021 8:19 AM Jay Lutz 0 Comments Mind Medicine, MindMed

MindMed (NEO: MMED) this morning announced that it has begun a study on what it refers to as “LSD neutralizer

Briefing Psychedelics

MindMed Launches Clinical Trial Focused On Combining LSD With MDMA

January 20, 2021 8:09 AMJanuary 20, 2021 8:10 AM Jay Lutz 1 Comment Mind Medicine, MindMed

Mind Medicine (NEO: MMED) has begun the first clinical trials focused on combining MDMA and LSD. The trials, to be

Briefing Psychedelics

Mind Medicine Raises $92.1 Million Via Bought Deal Financing

January 7, 2021 9:31 AMJanuary 7, 2021 9:32 AM Jay Lutz 0 Comments Mind Medicine, MindMed

Mind Medicine (NEO: MMED) has closed its previously announced bought deal financing, raising nearly double the initial $50.0 million the

Briefing Psychedelics

MindMed Closes $34.5 Million Financing, Cash Reserves Said To Be At $85 Million

December 11, 2020 9:15 AMDecember 11, 2020 9:15 AM Jay Lutz 0 Comments Mind Medicine, MindMed

Mind Medicine (NEO: MMED) has completed its previously announced bought deal private placement, raising gross proceeds of $34.5 million. The

Briefing Psychedelics

Mind Medicine Returns To Trough For Further $25.0 Million

November 25, 2020 9:25 AMNovember 25, 2020 9:25 AM Jay Lutz 0 Comments Mind Medicine, MindMed

Mind Medicine (NEO: MMED) continues to take investor dollars, this morning announcing a bought deal private placement for $25.0 million.

Briefing Psychedelics

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

November 17, 2020 10:17 AMNovember 17, 2020 10:02 AM Justin Young 0 Comments Analyst Estimate, Mind Medicine, MindMed

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results. Tania Gonsalves, Canaccord Genuity’s biotechnology

Briefing Psychedelics

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

November 2, 2020 10:45 AMNovember 2, 2020 10:50 AM Justin Young 2 Comments Analyst Estimate, Mind Medicine, MindMed

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from C$1.75 to C$2.00 while reiterating

Briefing Psychedelics

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

September 16, 2020 4:15 PMSeptember 16, 2020 3:16 PM Justin Young 0 Comments Analyst Estimate, Mind Medicine, MindMed

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and a C$1.75 price target. Canaccord’s

Briefing Psychedelics

MindMed Adds MDMA To R&D Pipeline

May 27, 2020 9:00 AMMay 27, 2020 9:00 AM Jay Lutz 0 Comments Mind Medicine, MindMed

Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching out its research and development

← Previous